These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26181549)

  • 1. Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Su FC; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Cherng WJ; Chen TH
    Medicine (Baltimore); 2015 Jul; 94(28):e1128. PubMed ID: 26181549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
    Weir DL; McAlister FA; Senthilselvan A; Minhas-Sandhu JK; Eurich DT
    JACC Heart Fail; 2014 Dec; 2(6):573-82. PubMed ID: 24998080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
    Wang SH; Chen DY; Lin YS; Mao CT; Tsai ML; Hsieh MJ; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    PLoS One; 2015; 10(6):e0131122. PubMed ID: 26115092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study.
    Liang CY; Chen DY; Mao CT; Hsieh IC; Hung MJ; Wang CH; Wen MS; Cherng WJ; Chen TH
    Medicine (Baltimore); 2018 Dec; 97(52):e13844. PubMed ID: 30593182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study.
    Yang TY; Liaw YP; Huang JY; Chang HR; Chang KW; Ueng KC
    Acta Diabetol; 2016 Jun; 53(3):461-8. PubMed ID: 26687195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
    Eurich DT; Simpson S; Senthilselvan A; Asche CV; Sandhu-Minhas JK; McAlister FA
    BMJ; 2013 Apr; 346():f2267. PubMed ID: 23618722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
    Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
    Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
    Chan SY; Ou SM; Chen YT; Shih CJ
    Int J Cardiol; 2016 Sep; 218():170-175. PubMed ID: 27236110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.
    Cai B; Katz L; Alexander CM; Williams-Herman D; Girman CJ
    Int J Clin Pract; 2010 Nov; 64(12):1601-8. PubMed ID: 20946268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
    Mohan V; Yang W; Son HY; Xu L; Noble L; Langdon RB; Amatruda JM; Stein PP; Kaufman KD
    Diabetes Res Clin Pract; 2009 Jan; 83(1):106-16. PubMed ID: 19097665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
    Scheen AJ; Paquot N
    Rev Med Liege; 2015 Oct; 70(10):511-6. PubMed ID: 26727841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.